scrn2 Antibody

What is SCRN2 and what are its known cellular functions?

SCRN2 (Secernin-2) is a 425 amino acid protein that belongs to the peptidase C69 family and the Secernin subfamily, playing critical roles in regulating cellular secretion and vesicle transport mechanisms . The protein is involved in various cellular processes including exocytosis and membrane trafficking, making it an essential component in understanding mechanisms underlying various physiological and pathological conditions . SCRN2 is part of a gene family that has three vertebrate paralogs: SCRN1, SCRN2, and SCRN3, which are closely linked to human HOXA, HOXB, and HOXD clusters, respectively . Vertebrate SCRN genes show a topology of the form (A)(BC), where SCRN2 falls outside the SCRN3-SCRN1 cluster . The SCRN2 gene maps to human chromosome 17q21.32, a region associated with various conditions including neurofibromatosis . Current research suggests potential involvement of SCRN2 in diseases such as cancer, neurodegenerative disorders, and metabolic syndromes, making it a valuable target for scientific investigation .

What types of SCRN2 antibodies are available for research?

Researchers have access to several types of SCRN2 antibodies, with polyclonal rabbit antibodies being the most commonly documented in the available literature . These antibodies are typically generated using recombinant fusion proteins containing specific amino acid sequences from human SCRN2 as immunogens . For instance, some commercially available antibodies utilize recombinant fusion proteins corresponding to amino acids 176-425 of human SCRN2 (NP_612364.2) as the immunogen . The antibodies are generally available in unconjugated forms, purified through antigen affinity methods, and formulated in buffer solutions containing phosphate-buffered saline (PBS) with glycerol concentrations ranging from 40-50% and preservatives like sodium azide (NaN3) . Most SCRN2 antibodies demonstrate reactivity to human, mouse, and rat samples, making them versatile tools for comparative studies across species . These antibodies are extensively validated for applications including Western blot, immunohistochemistry, immunofluorescence, and ELISA, with recommended dilution ranges specific to each application method .

Which experimental techniques are most effective with SCRN2 antibodies?

SCRN2 antibodies have been validated for multiple experimental techniques, with Western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF), and ELISA being the most commonly documented applications . For Western blot applications, SCRN2 antibodies show effective detection at dilution ranges of 1:500-1:2000, with some sources specifically recommending 1:400 dilution for optimal results . Immunohistochemistry applications typically use more concentrated antibody solutions, with recommended dilutions of 1:50-1:300 or specifically 1:60 for paraffin-embedded tissue sections . Immunofluorescence applications have been validated with dilution ranges of 0.25-2 μg/mL, allowing researchers to visualize SCRN2 localization at the subcellular level . For ELISA applications, SCRN2 antibodies have demonstrated reliable detection capabilities, though specific optimization may be required for different experimental setups . The versatility of SCRN2 antibodies across these techniques makes them valuable tools for comprehensive protein characterization, enabling researchers to investigate expression patterns, localization, and interactions in various experimental contexts .

What tissue and cell types are optimal for studying SCRN2 expression?

Several tissue and cell types have been validated for studying SCRN2 expression using antibody-based detection methods . Mouse small intestines tissue has been specifically identified as a validated sample type for Western blot analysis of SCRN2 expression . For immunohistochemical studies, human lung cancer tissue sections have been successfully used to detect SCRN2 at a dilution of 1:60 . Human tonsil tissue also serves as an effective sample for immunohistochemical detection of SCRN2 using similar dilution parameters (1:60) . Human esophageal cancer tissue has been documented as another verified sample for immunohistochemical analysis of SCRN2 expression . The verification of these specific tissue types indicates that SCRN2 is expressed at detectable levels in these samples, making them suitable positive controls for experimental validation . For subcellular localization studies, SCRN2 has been described as present in the extracellular region or secreted, as well as in extracellular exosomes, suggesting that cell types involved in active secretion may be particularly relevant for studying SCRN2 function .

How should researchers optimize antibody dilutions for different applications?

Optimization of SCRN2 antibody dilutions requires systematic titration based on the specific application and experimental conditions . For Western blot applications, researchers should begin with the manufacturer's recommended range of 1:500-1:2000 and perform a dilution series to determine optimal signal-to-noise ratio for their specific samples . When conducting immunohistochemistry, a more concentrated antibody solution is typically required, with starting dilutions in the range of 1:50-1:300 . The optimization process should include positive and negative controls to verify specificity at each dilution tested . For immunofluorescence applications, manufacturers typically recommend concentrations between 0.25-2 μg/mL, with the specific concentration dependent on the fixation method, cell type, and detection system used . When optimizing dilutions, researchers should consider factors such as the abundance of the target protein in their samples, the sensitivity of their detection system, and the quality of their tissue preparation or protein extraction .

How can researchers troubleshoot unexpected Western blot results with SCRN2 antibodies?

When encountering unexpected Western blot results with SCRN2 antibodies, researchers should first consider that the observed molecular weight may differ from the calculated 47 kDa due to various factors affecting protein mobility . The presence of multiple bands may indicate different modified forms of SCRN2 coexisting in the sample, which should be carefully analyzed rather than immediately dismissed as non-specific binding . Researchers should verify sample preparation protocols, ensuring complete denaturation and reduction of proteins, as incomplete processing can result in aberrant migration patterns . Optimizing blocking conditions is crucial for reducing background and non-specific binding, with 5% non-fat dry milk or bovine serum albumin (BSA) in TBST (Tris-buffered saline with Tween-20) commonly used for SCRN2 antibody applications . Careful consideration of exposure times during imaging is essential, as overexposure can lead to detection of weak cross-reactivity that may be misinterpreted as multiple SCRN2 isoforms . If inconsistent results persist, researchers should validate the antibody using positive control samples that have been previously confirmed to express SCRN2, such as mouse small intestines tissue lysate .

What are the best practices for storage and handling of SCRN2 antibodies?

To maintain optimal performance of SCRN2 antibodies, researchers should adhere to specific storage and handling guidelines . SCRN2 antibodies should be stored at -20°C with glycerol (typically 40-50%) as a cryoprotectant to prevent freeze-thaw damage . Repeated freeze-thaw cycles significantly reduce antibody activity, so researchers should aliquot the stock solution into smaller volumes upon receipt to minimize the number of freeze-thaw cycles . When working with the antibody, it should be thawed on ice or at 4°C rather than at room temperature to preserve its structural integrity and binding affinity . Prior to opening, centrifuging the vial briefly ensures complete recovery of the contents, particularly important for small volume antibody preparations . Working dilutions of the antibody should be prepared fresh for each experiment rather than stored for extended periods to prevent degradation and maintain consistent performance . The antibody should be handled with appropriate personal protective equipment due to the presence of preservatives such as sodium azide (NaN3), which is toxic and requires proper disposal considerations .

How do post-translational modifications affect SCRN2 detection?

Post-translational modifications (PTMs) can significantly impact SCRN2 detection using antibody-based methods, potentially altering epitope accessibility and protein mobility during analysis . The actual observed molecular weight of SCRN2 in Western blot applications may differ from the calculated 47 kDa due to PTMs such as phosphorylation, glycosylation, ubiquitination, or proteolytic processing, which can either increase or decrease the apparent molecular weight . These modifications may affect antibody recognition if they occur within or adjacent to the epitope region, potentially leading to decreased signal intensity or even complete loss of detection . When investigating SCRN2 in different cellular contexts or physiological states, researchers should consider that PTM patterns may vary, resulting in tissue-specific or condition-specific detection profiles . To account for these variables, researchers working with SCRN2 antibodies should run appropriate controls and consider using complementary detection methods or multiple antibodies targeting different epitopes of the protein . Some commercially available SCRN2 antibodies specifically note their target as "unmodified" SCRN2, indicating they may not recognize certain post-translationally modified forms of the protein .

How can SCRN2 antibodies be used in cancer research?

SCRN2 antibodies offer valuable tools for investigating the potential roles of this protein in cancer development and progression across multiple experimental platforms . Immunohistochemistry applications using SCRN2 antibodies have been validated for human lung cancer and esophageal cancer tissues, allowing researchers to evaluate expression patterns and localization within tumor microenvironments . Through comparative analysis of SCRN2 expression in normal versus malignant tissues, researchers can identify potential associations with cancer progression, metastasis, or treatment response . Western blot analysis using SCRN2 antibodies enables quantitative assessment of expression levels across different cancer cell lines or patient-derived samples, facilitating the identification of cancer types where SCRN2 may play particularly significant roles . The involvement of SCRN2 in membrane trafficking and secretory pathways suggests potential roles in tumor cell communication, extracellular matrix remodeling, or exosome-mediated signaling, all of which can be explored using appropriate antibody-based techniques . Researchers investigating cancer biology can utilize SCRN2 antibodies in conjunction with other cancer markers to develop more comprehensive understanding of signaling networks and potential therapeutic targets .

What are effective methods for studying SCRN2 involvement in exocytosis and membrane trafficking?

To investigate SCRN2's role in exocytosis and membrane trafficking, researchers can employ multiple antibody-based approaches in combination with specialized techniques for studying vesicular transport . Co-immunoprecipitation experiments using SCRN2 antibodies can identify protein interaction partners within the secretory pathway, providing insights into the molecular complexes that regulate vesicle formation, transport, and fusion . Immunofluorescence microscopy with SCRN2 antibodies combined with markers for different vesicular compartments (such as Rab GTPases, SNARE proteins, or cargo molecules) can reveal the specific subcellular localization and trafficking dynamics of SCRN2 during exocytosis . Live-cell imaging approaches using fluorescently tagged SCRN2 antibody fragments can track the movement of SCRN2-containing vesicles in real-time, though careful validation is necessary to ensure antibody binding doesn't interfere with normal protein function . For studying SCRN2's role in regulated secretion, researchers can combine antibody detection with secretion assays in model cell types such as neuroendocrine cells or immune cells, correlating SCRN2 expression or localization with secretory capacity . The extracellular localization and presence in exosomes noted for SCRN2 suggests it may function in unconventional secretion pathways, which can be investigated using gradient fractionation followed by Western blot detection with SCRN2 antibodies .

How can SCRN2 expression be accurately quantified across different tissue types?

Accurate quantification of SCRN2 expression across different tissue types requires a multi-method approach combining antibody-based detection with complementary techniques . Western blot analysis using SCRN2 antibodies provides semi-quantitative assessment of total protein levels, with densitometric analysis allowing comparison between different samples when normalized to appropriate loading controls such as GAPDH or β-actin . For higher throughput quantification across multiple tissue types, tissue microarray (TMA) analysis with immunohistochemical staining using SCRN2 antibodies can be employed, with standardized scoring systems applied to evaluate expression intensity and distribution patterns . When subtle differences in expression require detection, quantitative immunofluorescence microscopy with careful standardization of antibody concentrations, incubation times, and imaging parameters can provide more sensitive measurements . For absolute quantification, researchers can develop ELISA-based assays using SCRN2 antibodies, with standard curves generated using recombinant SCRN2 protein of known concentration . RNA-level expression data can complement protein-level quantification, providing insights into transcriptional regulation of SCRN2 across tissues, though researchers should be aware that RNA and protein levels may not always correlate perfectly .

What is the relationship between SCRN2 and other secernin family members in experimental models?

Understanding the relationship between SCRN2 and other secernin family members (SCRN1 and SCRN3) requires careful experimental design using selective antibodies and complementary approaches . The secernin gene family consists of three vertebrate paralogs (SCRN1, SCRN2, and SCRN3) which share structural similarities but potentially differ in their tissue distribution and functional roles . When designing experiments to differentiate between secernin family members, researchers should carefully evaluate antibody specificity to ensure selective detection of SCRN2 without cross-reactivity to SCRN1 or SCRN3, particularly when studying tissues where multiple family members may be expressed . Phylogenetic analysis indicates that SCRN2 falls outside the SCRN3-SCRN1 cluster, suggesting potentially divergent functions that could be explored through comparative expression studies using selective antibodies for each family member . The genomic organization of secernin genes, with SCRN2 linked to the HOXB cluster on chromosome 17, while SCRN1 and SCRN3 are linked to HOXA and HOXD clusters respectively, hints at evolutionary relationships that may inform functional studies . For comprehensive characterization, researchers might employ knockdown or knockout models for individual secernin family members, followed by immunodetection of the remaining members to assess potential compensatory mechanisms or functional redundancy .

How can dual staining with SCRN2 and other markers be optimized for confocal microscopy?

Optimizing dual immunostaining protocols for SCRN2 and other markers requires careful consideration of antibody compatibility, fluorophore selection, and staining procedures to achieve high-quality confocal microscopy results . When selecting primary antibodies for co-staining with SCRN2, researchers should choose antibodies raised in different host species (e.g., rabbit anti-SCRN2 combined with mouse antibodies against other markers) to enable straightforward discrimination using species-specific secondary antibodies . If using multiple rabbit-derived antibodies is unavoidable, sequential staining protocols with intermediate blocking steps or direct conjugation of one antibody to a fluorophore may be necessary to prevent cross-reactivity . Fluorophore selection should account for spectral overlap and microscope capabilities, with widely separated excitation/emission spectra preferred to minimize bleed-through; common pairs include Alexa Fluor 488/594 or FITC/TRITC for dual staining with SCRN2 antibodies . Optimal fixation methods may vary depending on the specific markers being co-detected with SCRN2, with paraformaldehyde fixation (4%) commonly used for maintaining both SCRN2 epitopes and cellular architecture . When optimizing staining protocols, researchers should systematically adjust factors including antibody concentrations, incubation times and temperatures, blocking solutions, and washing stringency to maximize specific signal while minimizing background .

What considerations should be made when using SCRN2 antibody in co-immunoprecipitation experiments?

Co-immunoprecipitation (Co-IP) experiments using SCRN2 antibodies require careful optimization to effectively capture protein complexes while minimizing non-specific interactions and preserving physiologically relevant associations . When selecting an SCRN2 antibody for Co-IP applications, researchers should prioritize antibodies specifically validated for immunoprecipitation rather than assuming Western blot-validated antibodies will perform effectively in precipitation contexts . The lysis buffer composition is critical for preserving protein-protein interactions while effectively solubilizing membrane-associated proteins like SCRN2; non-ionic detergents like NP-40 or Triton X-100 at 0.5-1% are often suitable starting points, with optimization based on specific experimental requirements . Pre-clearing lysates with protein A/G beads before adding the SCRN2 antibody can reduce non-specific binding, particularly important when working with complex tissue lysates rather than cultured cell lines . Researchers should carefully optimize antibody amounts and incubation conditions, typically starting with 1-5 μg of antibody per 0.5-1 mg of total protein lysate, incubated overnight at 4°C with gentle rotation to maximize specific interactions while minimizing background . For detecting novel interaction partners, stringent washing conditions may reduce false positives, while more gentle washing may preserve weaker but physiologically relevant interactions; optimization through systematic testing is recommended .